Généthon

Généthon

First a pioneer of human genome research, Genethon now explores the new therapeutic hypotheses stemming from the extraordinary progresses of contemporary biology.

Today, Genethon is a charity-funded biotherapy organization, financed at 88.7% by the AFM, Under the management of Dr Frédéric Revah, CEO, Genethon is a unique structure where researchers, technicians, chemists and physicians elaborate technologies to develop innovative therapeutics, like gene therapy or cell therapy, to treat rare or orphan diseases. Scientists of Genethon focus on therapeutic tools for in vivo or ex vivo gene transfer, on rare diseases and specifically on neuromuscular diseases as well as on immune system or skin diseases. These pathologies are real models to help accelerate the research towards new therapeutic concepts which can subsequently be adapted to more well-known pathologies.


For gene therapy and cell culture, a large engineering team then develops vector manufacturing processes that are transferred to our GMP production service, accredited as Gene and Cell Therapy Establishment (Etablissement de thérapie génique et cellulaire -ETGC). The latter provides GMP quality controlled vectors, not only for Généthon’s own projects but for numerous collaborations or external requests. Today we can manufacture vectors for use in gene therapy clinical trials. In view of increasing the production capacity, Généthon has inaugurated the novel bioproduction center (Généthon BioProd) on the 30th of November 2010, allowing the production of clinical grade viral vectors for phase I and II clinical studies at production scales going up to 200 L per reactor run.
Involved in WP: 7, 8, and TACT.

Address
1bis, Rue de l'Internationale
BP60
Évry Cédex
F-91002
France


Website www.genethon.fr

 

Didier Caizergues Didier Caizergues

Didier is a pharmacist specialized in Regulatory Affairs as well as in product development.  He has been working at  GENETHON since 2001 where he has successfully obtained Orphan Drugs designations and Clinical Trial Authorizations for gene therapy products in the field of NMDs and primary immune deficiencies  in several European countries.

More Info

 

Anne Marie Douar

Anne Douar has a degree in human genetics. She has been working at Généthon since 1997 where she was in charge of vector development. Since 2009 she is in charge of business development and strategic partnership.

More Info

Call 0033 1-69-47-10-24

 

Yves Fromes

Yves Fromes (MD, Ph.D.) is Head of the department of Preclinical Development at Genethon.

More Info

 

Stéphane Roques Stéphane Roques

In January 2009, Stéphane Roques became Secretary General of Généthon - the AFM's research arm, which is seeking to demonstrate the efficacy of gene therapy for rare diseases in general and neuromuscular diseases in particular.


More Info

 

Frédéric Revah

Immediately prior to joining [Généthon] in January 2010, Frédéric Revah had been Chief Executive Officer of the oncology start-up Sepal Pharma since 2008. Before that, he had served as Vice President, Drug Discovery, and Chief Scientific Officer Director at the NYSE Euronext-listed biotech company Cerep from 1999 to 2007 and Chief Executive Officer of its oncology subsidiary.

More Info

Call 0033 1-69-47-12-85

 

Otto-Wilhelm Merten Otto-Wilhelm Merten

Otto-Wilhelm Merten has a degree in biotechnology. He has been working at Généthon since 1997 where he was in charge of the bioprocess development department for development of large scale manufacturing processes of viral vectors. Today he directs the group of applied vectorology and innovation.

More Info

 

Hafedh Haddad Hafedh Haddad

Hafedh Haddad is a medical doctor with a master in clinical research. He joined GENETHON in 2005 to lead its 1st clinical project: the gamma-sarcoglycanopathy (LGMD 2C) project. He has since then been leading GENETHON's clinical research activity, including the set up and the management of the ex vivo gene therapy trial in Wiskott-Aldrich Syndrome.

More Info

 

Isabelle Richard Isabelle Richard

Since her PhD studies in 1991, Isabelle has been working on Limb Girdle Muscular Dystrophies: identification of the genes and study of their protein functions to identify pharmacological solutions, development of animal models and investigation of gene transfer by gene therapy.

More Info